Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 34 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
24 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
ExoXpert from Liège, company number BE1003807666, closed financial year 2025 with a result of € -1.7 million after tax. For that financial year ExoXpert recorded revenue of € 42,100 and equity of € -3.9 million. Compared with financial year 2024, the result moved from € -2.2 million to € -1.7 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.
€ -3.9 million
▼ € 1.7 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.7 million
▲ 24 % less loss than in 2024
Profit after tax over the fiscal year.
€ 4,919
▼ 56% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -4 million.
People and assets in 2025
8.3
▼ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 862,074
▼ 12% vs 2024
€ 103,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3.5 million
▲ 46% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 321,711
▼ 28% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Revenue | - | € 42,100 | |
| Gross margin | € 1,059,557 | € 726,952 | ▼ 31% |
| Profit after taxes | € -2,240,370 | € -1,709,778 | ▲ € 530,592 |
| Equity | € -2,190,370 | € -3,900,147 | ▼ € 1.7 million |
| Total debts | € 3,228,637 | € 5,950,735 | ▲ 84% |
| Cash | € 11,081 | € 4,919 | ▼ 56% |
| Retained profit | € -2,240,370 | € -3,950,147 | ▼ € 1.7 million |
| Balance sheet total | € 1,038,268 | € 2,050,587 | ▲ 98% |
| Employees (FTE) | 8.8 | 8.3 | ▼ 0.5 |
Key figures of ExoXpert, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ExoXpert?
What happened at ExoXpert in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1.7 million. Source: NBB ↗
- New establishment in Liège. KBO
- Start of the company according to the CBE. KBO
- Stijn Van Rompay became a director. NBB
In short
From € 2.2 million loss in 2024 to € 1.7 million loss in 2025.
Paid € 1,779 in corporate taxes since 2024.
On average € 87,600 of value added per employee in 2025.
A new publication or filing at ExoXpert? We notify you, reason included.
Follow ExoXpertDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of EXO Biologics comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ExoXpertBehind ExoXpert is Stijn Van Rompay . The shares are held by EXO Biologics (100%).
Directors
According to the 2025 annual accounts
Stijn Van Rompay
Director
Also active at: J.D.P. Consult, SVR INVEST, SVR Management, DERMAX, Hyloris, Hyloris Pharmaceuticals, EXO Biologics, PE GROUP +1 more
since 2023
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3 box 2
4000 Liège
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 24 companies are registered at this address.
All companies at this address →Hyloris Developments
€ 5.1 million revenue · 2025
ONCORADIOMICS
€ 2.4 million gross margin · 2025
DERMAX same network
€ 1.6 million revenue · 2025
Hyloris same network
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals same network
€ 3.8 million revenue · 2025
+19 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1003.807.666
- VAT number
- BE 1003.807.666
- Registered office
- Boulevard de Patience et Beaujonc 3 bus 2, 4000 Liège
- Names & denominations
- ExoXpert
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 December 2023
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Vervaardiging van overige farmaceutische producten
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Groothandel in farmaceutische en medische artikelen
Overige gespecialiseerde wetenschappelijke en technische activiteiten